Fort Lauderdale, FLORIDA2 Active Studies

Pulmonary Embolism Clinical Trials in Fort Lauderdale, FLORIDA

Find 2 actively recruiting pulmonary embolism clinical trials in Fort Lauderdale, FLORIDA. Connect with local research sites and explore new treatment options.

2
Active Trials
2
Sponsors
1,100
Enrolling

Recruiting Pulmonary Embolism Studies in Fort Lauderdale

About Pulmonary Embolism Clinical Trials in Fort Lauderdale

Pulmonary embolism (PE) is a blockage of an artery in the lungs, usually caused by blood clots that travel from the deep veins of the legs. It can be life-threatening and requires immediate medical attention. Treatment includes anticoagulants and in severe cases, thrombolytic therapy.

There are currently 2 pulmonary embolism clinical trials recruiting participants in Fort Lauderdale, FLORIDA. These studies are seeking a combined 1,100 participants. Research is being sponsored by Eli Lilly and Company, Cytokinetics. Clinical trial participation is free and participants receive study-related medical care at no cost.

Pulmonary Embolism Clinical Trials in Fort Lauderdale — FAQ

Are there pulmonary embolism clinical trials in Fort Lauderdale?

Yes, there are 2 pulmonary embolism clinical trials currently recruiting in Fort Lauderdale, FLORIDA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Fort Lauderdale?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Fort Lauderdale research site will contact you about next steps.

Are clinical trials in Fort Lauderdale free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Fort Lauderdale studies also compensate for your time and travel.

What pulmonary embolism treatments are being tested?

The 2 active trials in Fort Lauderdale are testing new therapies including novel drugs, biologics, and treatment approaches for pulmonary embolism.

Data updated March 2, 2026 from ClinicalTrials.gov